Objective To investigate the patterns of estradiol-oocyte ratio (EOR) and estradiol-mature oocyte ratio (EMOR) in patients with breast cancer undergoing controlled ovarian stimulation (COS) using letrozole and gonadotropins for fertility preservation. Methods This retrospective study included 32 breast cancer patients underwent COS for fertility preservation and no patients had previously und...

While ovarian tissue cryopreservation has commonly been equated with fertility preservation in cancer patients, there is a range of alternative options to preserve fertility. Based on the type and timing of chemotherapy, the type of cancer, the patient's age and the partner status, a different strategy of fertility preservation may be needed. If the patient has a partner or accepts donor sperm,...

OBJECTIVE To describe a case series of seven women with SLE and other systemic autoimmune rheumatic diseases (SARDs) who required cyclophosphamide therapy and underwent fertility preservation treatments. METHODS Of the seven patients reported here, five women had SLE with nephritis, the sixth had immune thrombocytopenia purpura (ITP) and the seventh had microscopic polyangiitis (MPA) with ren...

As the efficacies of anticancer therapies were increase and quite efficient early diagnoses have been taken place in gynecological cancer, increased long-term survival of cancer patients and long-term complications of anticancer treatments are being encountered. The lost of ovarian reserve or function due to gonadal toxicity is the major problem that mainly focused. A wide range of new fertilit...

BACKGROUND This prospective, Phase IV, multicenter, observational registry of assisted reproductive technology clinics in the USA studied outcomes of first cycles using thawed/warmed cryopreserved (by slow-freezing/vitrification) oocytes (autologous or donor). METHODS Patients were followed up through implantation, clinical pregnancy, and birth outcomes. The main outcome measure was live birt...

BACKGROUND It has been recommended by the American Society of Clinical Oncology and the American Society of Reproductive Medicine that options to preserve fertility be presented at the outset of treatment for cancer. This recommendation may have arisen, in part, to the increasing survival of patients with cancer and the realization that certain forms of cancer treatment can lead to infertility....

The issue of fertility preservation in patients with cervical cancer is getting more and common considering the improved effectiveness early diagnosis treatment cancer. There a number evidence-based tactics available to diagnosed These have been proved effective include methods such as ovarian transposition; oocyte, embryo tissue cryopreservation. Nonetheless, there are no existing medical algo...

oocyte, embryo and ovarian tissue cryopreservation are being increasingly proposed for fertility preservation among cancer patients undergoing therapy to enable them to have babies after the cancer is cured. embryo cryopreservation is not appropriate for single girls without any sperm partner and also because oocyte retrieval is an extended procedure, it is impossible in cases requiring immedia...

Growing evidence of successful outcomes achieved with the oocyte vitrification technique has greatly contributed to its application in field fertility preservation (FP). The population that can benefit from FP includes women at a risk losing their ovarian function because either iatrogenic causes or natural depletion reserve. Therefore, oncological patients and healthy who wish delay motherhood...